Literature DB >> 28240663

68Ga-DOTATATE PET/CT in Nonneuroendocrine Tumors: A Pictorial Essay.

Lilian Yuri Itaya Yamaga1, Jairo Wagner, Marcelo Buarque de Gusmão Funari.   

Abstract

PET-CT with somatostatin analogs labeled with Ga is increasingly recognized as the best imaging modality for the evaluation of well-differentiated neuroendocrine tumors (NETs). However, somatostatin receptor (SSR) is not an exclusive marker for NET. A variety of tumors other than NETs express SSR, leading to a significant risk of false-positive PET/CT results. We illustrate false-positive Ga-DOTATATE PET/CT findings due to high uptake by non-Hodgkin lymphoma, metastatic meningioma, breast cancer, thyroid adenoma, and papillary carcinoma. Although Ga-DOTATATE is a noteworthy tracer for oncological application, pathological conditions with overexpression of SSR should be recognized to prevent misinterpretation of PET/CT images.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28240663     DOI： 10.1097/RLU.0000000000001620

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  8 in total

Review 1.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 2.  Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations.

Authors:  W Tania Rahman; Colleen H Neal; Alexis Virginia Nees; Richard K J Brown
Journal:  Radiol Imaging Cancer       Date:  2020-03-20

3.  Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma.

Authors:  Emily B Ambinder; Rudolf A Werner; Steven P Rowe
Journal:  Radiol Case Rep       Date:  2020-06-25

Review 4.  Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature.

Authors:  Morten Bentestuen; Farid Gossili; Charlotte Elberling Almasi; Helle Damgaard Zacho
Journal:  Cancer Imaging       Date:  2022-09-03       Impact factor: 5.605

5.  Comparison of diagnostic efficacy of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT in ectopic adrenocorticotropic hormone syndrome.

Authors:  Bing Zhang; Qiao He; Yali Long; Yuying Zhang; Xiaoyan Wang; Zhifeng Chen; Jianbo Liu; Xiangsong Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

6.  Primary hepatic neuroendocrine neoplasm: Long-time surgical outcome and prognosis.

Authors:  Changying Shi; Qian Zhao; Binghua Dai; Feng Xie; Jiamei Yang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

Review 7.  Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Sara Sheikhbahaei; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  Ann Nucl Med       Date:  2018-08-14       Impact factor: 2.668

8.  Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.

Authors:  Tiago Sampaio Vieira; Diogo Borges Faria; Conceição Souto Moura; Elsa Francisco; Sérgio Barroso; José Pereira de Oliveira
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.